A July 22, 2019 announcement (received via email) features an upcoming talk hosted by the local Café Scientifque community,

Our next café will happen on TUESDAY, JULY 30TH [2019] at 7:30PM in the back room at YAGGER’S DOWNTOWN (433 W Pender). Our speaker for the evening will be DR. VAHID RAEESI.

TARGETING HEAT FOR DISEASE TREATMENT

Vahid is a nanotechnologist specializing in the design and development of functional platforms for disease detection and treatment. He holds a PhD in nano-biomaterials from the University of Toronto during which, he engineered nanoscale heat generators for precise destruction of different cancer types and antibiotic-resistant infections. He pursued this concept during postdoctoral studies under a nanoparticle-aided radiotherapy program for advanced prostate cancer at Grand River Cancer Centre, Waterloo. His research has been published in high profile scientific journals and featured in UofT News, “The Varsity” newspaper and NatureAsia.

We hope to see you there!

As per usual I searched for more information about Dr. Raeesi and his topic. First, I was a little curious as to how someone based in Toronto was recruited for a* talk in Vancouver but it all became clear after seeing Dr. Raeesi’s LinkedIn profile which lists his current employer as Precision NanoSystems Inc. (PNI). The company has its corporate headquarters here in Vancouver and I’m guessing that employees from other offices come here from time to time.

While I was looking for more information about Dr. Raeesi and his work I found that PNI is part of something called the Nanomedicines Innovation Network (NMIN), which is currently being hosted by the University of British Columbia (UBC; Vancouver, Canada). NMIN’s About page includes a history of the organization (scroll down the About page to Vision and Mission where you will see Two buttons, Fast Facts and History on the right side of your screen) ,

NMIN is based on R&D efforts to develop nanomedicines that began in 1980 at the University of British Columbia (UBC). Funding from UBC Excellence Funds in 2016 allowed UBC-based scientists to establish links with investigators across Canada to develop a national nanomedicines program. This resulted in the successful NMIN application to the federal NCE program.

In 2019 NMIN was awarded five years of funding (2019-2024) from the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

NMIN researchers are located at 17 universities across Canada. Team members have contributed to the development of five of the 13 systemically-administered nanomedicines approved by the US FDA, the European EMA and Health Canada to treat human disease.

NMIN researchers, together with Canadian companies Arbutus Biopharma and Acuitas Therapeutics, developed the lipid nanoparticle technology (LNP) incorporated into a gene therapy nanomedicine (Onpattro) that was recently (August 2018) approved by the US FDA to treat an incurable hereditary disease known as hereditary amyloidogenic transthyretin (hATTR) amyloidosis. Onpattro is the first RNAi gene therapy drug to be approved by the US FDA.

The world-class capacity of the network is also illustrated by the strong commercialization record of NMIN researchers. NMIN researchers have co-founded more than 20 companies that now employ more than 500 people across Canada. As a result, Canada has become a leading global hub for the development and commercialization of nanomedicines.

Hope you have a good time at the talk should you be inclined to attend.

*’a’ was added to this sentence “First, I was a little curious as to how someone based in Toronto was recruited for talk in Vancouver but it all became clear after seeing Dr. Raeesi’s LinkedIn profile which lists his current employer as Precision NanoSystems Inc. (PNI).” to correct the grammar on July 3, 2020.